Europese Unie - Nederlands - EMA (European Medicines Agency)

krka, d.d., novo mesto  - lenalidomide hydrochloride monohydrate - multiple myeloma; myelodysplastic syndromes; lymphoma, follicular; lymphoma, mantle-cell - immunosuppressiva - multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 en 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a). multiple myelomalenalidomide krka as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide krka as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide krka in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. myelodysplastic syndromeslenalidomide krka as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate. mantle cell lymphomalenalidomide krka as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (see sections 4. 4 en 5. follicular lymphomalenalidomide krka in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - lenalidomide - multiple myeloma - immunosuppressiva - multiple myelomalenalidomide accord as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide accord as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4. 2) is geïndiceerd voor de behandeling van volwassen patiënten met eerder behandelde multipel myeloom die niet in aanmerking komen voor transplantatie. lenalidomide akkoord in combinatie met dexamethason is geïndiceerd voor de behandeling van multipel myeloom bij volwassen patiënten die minstens één eerdere therapie. follicular lymphomalenalidomide accord in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1 – 3a).

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 2,5 mg - capsule, hard - 2,5 mg - lenalidomide 2.5 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 5 mg - capsule, hard - 5 mg - lenalidomide 5 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 7,5 mg - capsule, hard - 7,5 mg - lenalidomide 7.5 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 10 mg - capsule, hard - 10 mg - lenalidomide 10 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 15 mg - capsule, hard - 15 mg - lenalidomide 15 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 20 mg - capsule, hard - 20 mg - lenalidomide 20 mg - lenalidomide

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - lenalidomide 25 mg - capsule, hard - 25 mg - lenalidomide 25 mg - lenalidomide

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - lenalidomide - multiple myeloma - immunosuppressiva - multiple myelomalenalidomide mylan as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. lenalidomide mylan as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. lenalidomide mylan in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy. follicular lymphomalenalidomide mylan in combination with rituximab (anti-cd20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (grade 1-3a).